Release Date: 09/08/11 14:11 Summary: Ceasing to be Substantial Shareholder following placement Price Sensitive: No Download Document 63.65KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%